190 related articles for article (PubMed ID: 36238196)
1. Semaglutide May Alleviate Hepatic Steatosis in T2DM Combined with NFALD Mice via miR-5120/ABHD6.
Li R; Ye Z; She D; Fang P; Zong G; Hu K; Kong D; Xu W; Li L; Zhou Y; Zhang K; Xue Y
Drug Des Devel Ther; 2022; 16():3557-3572. PubMed ID: 36238196
[TBL] [Abstract][Full Text] [Related]
2. Semaglutide alters gut microbiota and improves NAFLD in db/db mice.
Mao T; Zhang C; Yang S; Bi Y; Li M; Yu J
Biochem Biophys Res Commun; 2024 May; 710():149882. PubMed ID: 38583231
[TBL] [Abstract][Full Text] [Related]
3. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease.
Liu J; Tang T; Wang GD; Liu B
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31064820
[No Abstract] [Full Text] [Related]
4. MicroRNA-376b-3p ameliorates nonalcoholic fatty liver disease by targeting FGFR1 and regulating lipid oxidation in hepatocytes.
Wang XY; Lu LJ; Li YM; Xu CF
Life Sci; 2022 Nov; 308():120925. PubMed ID: 36057399
[TBL] [Abstract][Full Text] [Related]
5. MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator.
Zhuge B; Li G
Biochem Biophys Res Commun; 2017 Dec; 494(3-4):687-692. PubMed ID: 29107687
[TBL] [Abstract][Full Text] [Related]
6. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
Long JK; Dai W; Zheng YW; Zhao SP
Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
[TBL] [Abstract][Full Text] [Related]
7. 6-Gingerol Ameliorates Hepatic Steatosis via HNF4α/miR-467b-3p/GPAT1 Cascade.
Ahn J; Lee H; Jung CH; Ha SY; Seo HD; Kim YI; Ha T
Cell Mol Gastroenterol Hepatol; 2021; 12(4):1201-1213. PubMed ID: 34139323
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR.
Nie H; Song C; Wang D; Cui S; Ren T; Cao Z; Liu Q; Chen Z; Chen X; Zhou Y
Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3087-3094. PubMed ID: 28951211
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice.
Zhang ZC; Liu Y; Xiao LL; Li SF; Jiang JH; Zhao Y; Qian SW; Tang QQ; Li X
J Hepatol; 2015 Dec; 63(6):1466-75. PubMed ID: 26272872
[TBL] [Abstract][Full Text] [Related]
10. Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease.
Zhou M; Liu X; Wu Y; Xiang Q; Yu R
J Ethnopharmacol; 2024 Jul; 329():118160. PubMed ID: 38588985
[TBL] [Abstract][Full Text] [Related]
11. MiR-18 regulates lipid metabolism of non-alcoholic fatty liver disease via IGF1.
Yang H; Zhang B; Yu C
Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):237-241. PubMed ID: 38678599
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
Lin Y; Ding D; Huang Q; Liu Q; Lu H; Lu Y; Chi Y; Sun X; Ye G; Zhu H; Wei J; Dong S
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):869-882. PubMed ID: 28483554
[TBL] [Abstract][Full Text] [Related]
13. A nanodrug system overexpressed circRNA_0001805 alleviates nonalcoholic fatty liver disease via miR-106a-5p/miR-320a and ABCA1/CPT1 axis.
Li J; Qi J; Tang Y; Liu H; Zhou K; Dai Z; Yuan L; Sun C
J Nanobiotechnology; 2021 Nov; 19(1):363. PubMed ID: 34789275
[TBL] [Abstract][Full Text] [Related]
14. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
Liu X; Chen S; Zhang L
Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2.
Chen X; Ma H; Gao Y; Jin Y; Ning W; Hou Y; Su J
Bioengineered; 2021 Dec; 12(1):6738-6747. PubMed ID: 34511037
[TBL] [Abstract][Full Text] [Related]
16. LncRNA NEAT1 promotes hepatic lipid accumulation via regulating miR-146a-5p/ROCK1 in nonalcoholic fatty liver disease.
Chen X; Tan XR; Li SJ; Zhang XX
Life Sci; 2019 Oct; 235():116829. PubMed ID: 31484042
[TBL] [Abstract][Full Text] [Related]
17. MiR-17 family-mediated regulation of Pknox1 influences hepatic steatosis and insulin signaling.
Ye D; Lou G; Zhang T; Dong F; Liu Y
J Cell Mol Med; 2018 Dec; 22(12):6167-6175. PubMed ID: 30338914
[TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of microRNA 146b mimic to hepatocytes by lactosylated PDMAEMA nanoparticles for the treatment of NAFLD.
He S; Guo W; Deng F; Chen K; Jiang Y; Dong M; Peng L; Chen X
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):217-228. PubMed ID: 29560749
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
[TBL] [Abstract][Full Text] [Related]
20. Sodium butyrate ameliorates non-alcoholic fatty liver disease by upregulating miR-150 to suppress CXCR4 expression.
Zhang N; Qu Y; Qin B
Clin Exp Pharmacol Physiol; 2021 Aug; 48(8):1125-1136. PubMed ID: 33721354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
